Parameters for Holding Lovenox (Enoxaparin)

Introduction to Holding Parameters

The American College of Chest Physicians recommends holding enoxaparin when creatinine clearance falls below 30 mL/min, platelet count drops below 100,000/μL, active bleeding occurs, or within 12 hours before neuraxial procedures 1, 2

Severe renal impairment (CrCl <30 mL/min) is an absolute indication to hold therapeutic-dose enoxaparin due to drug accumulation and dramatically increased bleeding risk (OR 3.88, 95% CI 1.78-8.45) 1, 2
For patients with CrCl 30-60 mL/min, reduce dose by 75% rather than holding completely 3
Switch to unfractionated heparin (UFH) as the preferred alternative when CrCl <30 mL/min, as UFH does not accumulate renally 1, 2
Fondaparinux is contraindicated when CrCl <30 mL/min 1, 3

Hold enoxaparin for active major bleeding, defined as bleeding requiring transfusion of ≥2 units of packed red blood cells, intracranial hemorrhage, or bleeding into a critical organ 4, 5
Hold when platelet count <100,000/μL due to increased bleeding risk 3
Monitor for heparin-induced thrombocytopenia (HIT) if platelets drop >50% from baseline 3

For neuraxial anesthesia or spinal procedures, hold enoxaparin for a minimum of 12 hours after the last prophylactic dose (40 mg daily) or 24 hours after therapeutic dosing (1 mg/kg twice daily) 6
Maintain at least 8-hour interval between last LMWH dose and epidural catheter removal 6
Do not restart enoxaparin until at least 4 hours after catheter removal 6

Hold enoxaparin 24 hours before major surgery with high bleeding risk 4
For emergency surgery, consider protamine sulfate partial reversal (1 mg protamine neutralizes ~1 mg enoxaparin, though only ~60% effective) 3

For patients ≥75 years, reduce dose to 0.75 mg/kg every 12 hours rather than holding, unless other contraindications exist 3, 6
Elderly patients have increased bleeding risk at standard doses due to decreased hepatic clearance and altered pharmacokinetics 3
Age alone is not an absolute contraindication, but requires dose adjustment and closer monitoring 3, 5, 7

For patients weighing ≤60 kg, consider holding or reducing dose due to increased drug concentration and bleeding risk 3, 6
Low body weight combined with other risk factors (age, renal impairment) compounds bleeding risk 6
Consider anti-Xa monitoring in underweight patients if continuing therapy 6

For patients with primary brain tumors or active intracranial malignancy, hold enoxaparin pending neurosurgical evaluation, as bleeding risk may outweigh thrombosis risk 5, 7
Brain metastases have lower intracranial hemorrhage risk than primary CNS tumors and may not require holding 7
Stable brain metastases are not an absolute contraindication to anticoagulation 7

Hold enoxaparin if anti-Xa level exceeds 1.0 IU/mL (therapeutic range 0.5-1.0 IU/mL for twice-daily dosing) 2
Anti-Xa monitoring is recommended when CrCl 30-60 mL/min 1, 7
Peak anti-Xa should be measured 4 hours after administration 2